Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics
A. B. Engelberg,
A. S. Kesselheim,
and
J. Avorn
- 14 Oct, 2009
This article requires a subscription.
Login via Athens or your institution
Already a print subscriber? Activate your online access
Not a Subscriber?
